Abbott's Transcatheter Mitral Valve Clip and Steerable Guide Catheter MitraClip® Approved in China, Offering New Hope for Heart Disease Patients

Recently, healthcare companyAbbottAnnounced its globally leading minimally invasive transcatheter mitral valve clip and steerable guide catheter, MitraClip®Approved by the National Medical Products Administration (NMPA) of China. It is a product approved by the NMPA and the U.S. Food and Drug Administration (FDA) and transcatheter valve therapy devices approved by the European Union for the treatment of mitral regurgitation, indicated for patients with significant symptomatic mitral regurgitation (Mitral Regurgitation, MR ≥ 3+) caused by primary mitral valve abnormalities (degenerative mitral regurgitation), who are deemed at high surgical risk by a heart team.

Mitral regurgitation is the most common valvular heart disease. Organic lesions of the valve leaflets, chordae tendineae, and papillary muscles, or dilation of the atria and ventricles leading to poor coaptation of the anterior and posterior mitral leaflets, result in mitral valve insufficiency, causing blood to flow backward from the left ventricle into the left atrium. Based on analysis and estimates from the echocardiography databases of Zhongshan Hospital Affiliated to Fudan University and the Second Affiliated Hospital of Zhejiang University School of Medicine, approximately 10 million patients in China require treatment for mitral regurgitation (MR ≥ 3+).1. Among these patients, some lost the opportunity for treatment or refused surgery due to high surgical risk. Moderate-to-severe mitral regurgitation can cause symptoms such as cough, dyspnea, and tachycardia, significantly impairing patients' physical function and quality of life. Without active treatment, it will increase the risk of heart failure, arrhythmias,Stroke, and even the risk of death.

Abbott's Globally Leading MitraClip®It is a minimally invasive transcatheter mitral valve repair procedure that provides an alternative treatment option for patients with moderate-to-severe mitral regurgitation who are at high surgical risk, enabling them to undergo a minimally invasive procedure without thoracotomy, without cardiopulmonary bypass support, with minimal trauma, short operative time, and high safety. To date, MitraClip®With 17 years of accumulated experience in research and development and clinical use, and over 100,000 cases worldwide, its entry into China will significantly optimize the existing treatment methods for mitral regurgitation in the country, better meet clinical needs, improve patients' quality of life, and bring new hope for health to the numerous Chinese patients with mitral regurgitation.

For over 130 years, Abbott has continuously advanced prevention by transforming cutting-edge technologies and products in life and health.Diagnosisinnovative breakthroughs in the therapeutic landscape, shaping the future of healthcare. In the field of structural heart disease, Abbott remains committed to providing Chinese patients with globally leading treatment solutions and innovative products to address disease needs including severe valvular stenosis/regurgitation, congenital heart disease, and the prevention of cardioembolic stroke, helping them return to healthy lives. As a milestone advancement in the field of interventional cardiovascular therapy, MitraClip®The successful approval also enables Abbott to help more Chinese patients live healthier and more fulfilling lives, while further driving the development and progress of the healthcare industry.